Back to News
Market Impact: 0.25
Aptevo Reports 93% Clinical Benefit With Mipletamig Triplet In TP53-Mutated AML; Stock Down 17%
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst Insights
Aptevo Therapeutics reported a 93% clinical benefit rate from its mipletamig triplet in evaluable frontline acute myeloid leukemia patients with TP53 mutations enrolled in the Phase 1b/2 RAINIER study. As an early-stage clinical-stage update, it is a meaningful efficacy signal but may have limited near-term impact beyond sentiment and biotech risk appetite.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
APVO0.55
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
- A 44-minute call and a memo: How Alexandr Wang won Mark Zuckerberg’s trust—and a $100 billion-plus AI bet
- TSMC posts a sixth straight record profit but turns cautious on 2027